Assignment 3(Week3)_ - TEVA PHARMACEUTICALS INDUSTRIES LTD...

TEVA PHARMACEUTICALS INDUSTRIES, LTD 1
TEVA PHARMACEUTICALS INDUSTRIES, LTD
Teva Pharmaceuticals Industries, Ltd.

TEVA PHARMACEUTICALS INDUSTRIES, LTD 2
Abstract
Pharmaceutical companies are undertaking major transformations to be able to manage the
innovative challenges of the contemporary economy. Some of the influences compelling these
transformations are adopting the business, the variety and intricacy of new drugs, and the fading
security offered by patents ( Papageorgiou & Shah, 2001 ). Operating in 60 countries with 46,000
employees worldwide, Teva is the largest generic drug manufacturer in the world. It clings to a
communal set of values and vision aside from being dynamic and diverse. This paper talks about
how Teva competes in the generic pharmaceutical industry and its competitive advantage.
Evaluating the company’s resources identifying the most valuable ones. In addition to that,
opportunities for Teva in innovative and generic pharmaceuticals will be discussed. Furthermore,
things the firm should consider moving forward for their continued success will also be
mentioned.
Keywords: Pharmaceutical, innovative, generic, competitive advantage

TEVA PHARMACEUTICALS INDUSTRIES, LTD 3
Teva Pharmaceuticals Industries, Ltd
Pharmaceutical companies are undertaking major transformations to be able to manage the
innovative challenges of the contemporary economy. Some of the influences compelling these
transformations are adopting the business, the variety and intricacy of new drugs, and the fading
security offered by patents. The emergent of new drugs to the organization of the industry and
allocation systems affects every phases of the corporate value chain (Papageorgiou & Shah,
2001).
Pharmaceutical firms are being required by market demands to interpret their product
portfolio in a more comprehensive view. The normal life cycles of latest medications are becoming
terser. Development of new product might take 8 years and the investment on it must be
recouped swiftly as generic counterparts can be developed at a later time that will decrease its
worth. Thus, businesses are continuously challenged with the question of the best consumption of